Get started
10x Genomics, Inc.10x Genomics, Inc.10x Genomics, Inc.

10x Genomics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

TXG chart


Full chart

TXG upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.64 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.53 USD
Net income (FY)
‪−255.10 M‬ USD
Revenue (FY)
‪618.73 M‬ USD
Shares float
‪99.73 M‬
Beta (1Y)
1.19

Employees


Employees (FY)
‪1.26 K‬
Change (1Y)
+16 +1.29%
Revenue / Employee (1Y)
‪491.44 K‬ USD
Net income / Employee (1Y)
‪−202.62 K‬ USD

About 10x Genomics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Serge Saxonov
Website
10xgenomics.com
Headquarters
Pleasanton
Founded
2012
FIGI
BBG007WX14X0
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

TXG news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TXG is 13.32 USD — it has decreased by −1.84% in the past 24 hours. Watch 10x Genomics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange 10x Genomics, Inc. stocks are traded under the ticker TXG.
TXG stock has fallen by −14.62% compared to the previous week, the month change is a −13.00% fall, over the last year 10x Genomics, Inc. has showed a −69.02% decrease.
We've gathered analysts' opinions on 10x Genomics, Inc. future price: according to them, TXG price has a max estimate of 30.00 USD and a min estimate of 14.00 USD. Watch TXG chart and read a more detailed 10x Genomics, Inc. stock forecast: see what analysts think of 10x Genomics, Inc. and suggest that you do with its stocks.
TXG reached its all-time high on Jun 29, 2021 with the price of 208.99 USD, and its all-time low was 13.30 USD and was reached on Nov 15, 2024. View more price dynamics on TXG chart.
See other stocks reaching their highest and lowest prices.
TXG stock is 4.83% volatile and has beta coefficient of 1.19. Track 10x Genomics, Inc. stock price on the chart and check out the list of the most volatile stocks — is 10x Genomics, Inc. there?
Today 10x Genomics, Inc. has the market capitalization of ‪1.64 B‬, it has decreased by −5.54% over the last week.
Yes, you can track 10x Genomics, Inc. financials in yearly and quarterly reports right on TradingView.
10x Genomics, Inc. is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
TXG earnings for the last quarter are −0.30 USD per share, whereas the estimation was −0.33 USD resulting in a 8.72% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about 10x Genomics, Inc. earnings.
10x Genomics, Inc. revenue for the last quarter amounts to ‪151.65 M‬ USD, despite the estimated figure of ‪156.89 M‬ USD. In the next quarter, revenue is expected to reach ‪153.37 M‬ USD.
TXG net income for the last quarter is ‪−35.75 M‬ USD, while the quarter before that showed ‪−37.90 M‬ USD of net income which accounts for 5.66% change. Track more 10x Genomics, Inc. financial stats to get the full picture.
No, TXG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has ‪1.26 K‬ employees. See our rating of the largest employees — is 10x Genomics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. 10x Genomics, Inc. EBITDA is ‪−133.38 M‬ USD, and current EBITDA margin is −25.58%. See more stats in 10x Genomics, Inc. financial statements.
Like other stocks, TXG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade 10x Genomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So 10x Genomics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating 10x Genomics, Inc. stock shows the sell signal. See more of 10x Genomics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.